# TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature

> **NCT02641847** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Fudan University** · enrollment: 503 (estimated)

## Conditions studied

- Triple Negative Breast Cancer
- Breast Cancer

## Interventions

- **DRUG:** docetaxel
- **DRUG:** doxorubicin or epirubicin
- **DRUG:** cyclophosphamide
- **DRUG:** gemcitabine
- **DRUG:** cisplatin

## Key facts

- **NCT ID:** NCT02641847
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-01
- **Primary completion:** 2023-12
- **Final completion:** 2027-12
- **Target enrollment:** 503 (ESTIMATED)
- **Last updated:** 2024-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02641847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02641847, "TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT02641847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*